On this page
Study tools
Write your answer
Saved on this device. No marking — you are the marker.
Q1: A 68-year-old man presents with 7 days of fever, dry cough, progressive dyspnoea, and new anosmia. SpO2 is 88% on room air, chest auscultation is surprisingly quiet. Discuss the diagnosis, the molecular mechanism of viral entry, and why the chest is so quiet despite the hypoxaemia. (2 min)
This is severe COVID-19 pneumonia caused by SARS-CoV-2, an enveloped, positive-sense, single-stranded RNA betacoronavirus of the subgenus Sarbecovirus, declared a pandemic by the WHO in March 2020. The clinical picture (typical symptom cluster of fever, dry cough, dyspnoea, anosmia in a high-risk patient) with SpO2 under 92% on room air meets severe-disease criteria. Viral entry requires two host-cell molecules working in sequence: the S1 subunit of the spike protein contains the receptor-binding domain (RBD) that binds the angiotensin-converting enzyme 2 (ACE2) receptor — densely expressed on type-II pneumocytes, nasal goblet and ciliated cells, bronchial epithelium, enterocytes, renal tubular cells, cardiomyocytes and vascular endothelium (explaining the multi-organ signature). After binding, the S2 subunit is primed by the transmembrane serine protease TMPRSS2, which cleaves S2 to expose the fusion peptide and drive membrane fusion at the cell surface; furin also pre-cleaves the polybasic S1/S2 site — a feature of SARS-CoV-2 (absent in SARS-CoV-1) that increases transmissibility. The viral RNA is then released into the cytoplasm, translated into polyproteins, and replicated by the RNA-dependent RNA polymerase (RdRp) — the molecular target of remdesivir. The chest being surprisingly quiet despite impressive hypoxaemia reflects the 'silent/happy hypoxaemia' phenotype of COVID-19: early disease often has preserved lung compliance (the 'Type-L' or low-elastance phenotype of Gattinoni) — the lungs are not stiff (so work-of-breathing and the sense of effort is not dramatically raised), yet there is profound intrapulmonary shunt and V/Q mismatch from vascular dysregulation, microthrombi, and loss of hypoxic pulmonary vasoconstriction. Auscultation therefore lags behind imaging and blood-gas severity. Clinical implication: always measure SpO2 on room air in every suspected case and use the 6-minute walk test or 1-minute sit-to-stand test to unmask exertional desaturation.
Q2: Outline the pathophysiology of severe COVID-19 from the cytokine storm to the hypercoagulable state, and how this informs drug choice. (3 min)
Severe COVID-19 is driven not by the virus itself (viral load has often peaked) but by a dysregulated host inflammatory response — the cytokine storm. The normal early innate response (type-I and type-III interferon) is delayed and blunted in severe disease, while a dysregulated macrophage-activation response releases IL-6, TNF-α, IL-1β, IL-12, MCP-1, and complement (C5a) activation, with lymphocyte apoptosis (the characteristic lymphopenia). This inflammatory phenotype is the rationale for dexamethasone 6 mg OD (RECOVERY — broad cytokine suppression, mortality benefit in oxygen-requiring patients only), tocilizumab 8 mg/kg IV (IL-6 receptor blockade — for rapidly progressing severe/critical disease with rising CRP/ferritin), and baricitinib 4 mg PO OD (JAK1/2 inhibition of intracellular cytokine signalling downstream of multiple receptors). On top of the inflammatory response, ACE2 is expressed on vascular endothelium; viral binding and internalisation produce diffuse endothelialitis, complement-mediated injury, and in-situ microthrombi. Combined with immobilisation and critical illness, this produces a striking prothrombotic state — the D-dimer is typically markedly raised, the rate of DVT and PE in hospitalised COVID-19 is several-fold higher than in matched non-COVID inpatients, and thromboses occur at unusual sites (cerebral venous sinus, splanchnic, mesenteric). This is the rationale for mandatory pharmacological VTE prophylaxis with low-molecular-weight heparin (enoxaparin 40 mg SC OD) in every hospitalised non-bleeding patient; therapeutic-dose anticoagulation is reserved for confirmed VTE or selected moderately-ill non-ICU patients with high D-dimer (REMAP-CAP/ATTACC/ACTIV-4a showed therapeutic anticoagulation was HARMFUL in critically ill ICU patients). A second mechanism worth mentioning: ACE2 normally converts Ang-II to Ang-(1-7) (vasodilatory, anti-inflammatory, anti-fibrotic); viral binding downregulates ACE2, leaving unopposed Ang-II, contributing to vasoconstriction, inflammation, fibrosis, and to the cardiac, renal and vascular injury seen in severe disease.
Q3: State the diagnostic investigations, the characteristic imaging findings, and the laboratory prognostic markers for severe COVID-19. (2 min)
Diagnostic test: the SARS-CoV-2 RT-PCR on a nasopharyngeal (or combined naso/oropharyngeal) swab is the gold standard; reported as a cycle-threshold (Ct) — a low Ct (under 25) indicates high viral load and infectivity; Ct over 35 typically corresponds to non-viable residual RNA. Rapid antigen tests (RAT) detect viral nucleocapsid antigen — faster and cheaper but less sensitive, especially early and in asymptomatics. Serology (anti-N antibodies) confirms prior infection and distinguishes natural infection from vaccination (vaccines target S only). Whole-genome sequencing identifies variants of concern. Chest imaging: the CXR is often normal early; classic finding is bilateral, peripheral, mid- and lower-zone opacities (ground-glass progressing to consolidation). Chest CT is the most sensitive imaging — the classic pattern is bilateral, peripheral (subpleural), posterior-basal ground-glass opacities (GGOs) with crazy-paving (GGO with interlobular septal thickening), consolidation, vascular enlargement, and (in organising phase) fibrotic bands and reverse-halo (atoll) sign. A ground-glass opacity is defined as a hazy increased lung attenuation without obscuration of underlying bronchovascular markings (distinguished from consolidation, which obscures them). Laboratory profile of severe disease — the high-yield inflammatory phenotype: lymphopenia (under 1.0 × 10⁹/L), raised CRP (50 to 200 mg/L), markedly raised ferritin (often over 1000), markedly raised D-dimer, raised LDH, raised IL-6, raised troponin and NT-proBNP in myocardial involvement, mild transaminitis, raised creatinine/AKI; coagulation may show mildly prolonged PT/aPTT with low fibrinogen in DIC-like states. Poor prognostic markers — older age, comorbidity (cardiac, diabetic, renal, obesity, immunocompromise), SpO2 below 92% on room air, raised D-dimer, ferritin, CRP, LDH, troponin, IL-6, low lymphocyte count, high neutrophil/lymphocyte ratio, low albumin, AKI, multilobar infiltrates, low PaO2/FiO2 ratio, vaccination non-receipt. For ARDS, use the Berlin definition (within 1 week; bilateral opacities; not cardiac; P/F with PEEP ≥5: mild 200-300, moderate 100-200, severe under 100).
Q4: Reproduce the severity-stratified management of COVID-19, with drugs, doses, routes, the trial that supports each, and the drugs you must NOT use. (3 min)
Therapy is stratified by severity and time-from-symptom-onset is critical (early = antiviral; late/inflammatory = immunomodulatory). Mild disease (SpO2 ≥92%, no pneumonia, home): supportive (rest, hydration, paracetamol 1 g QDS); isolate; antibiotics NOT routinely indicated. High-risk mild outpatient (within 5 to 7 days): nirmatrelvir 300 mg + ritonavir 100 mg PO BD for 5 days (Paxlovid — EPIC-HR trial, PMID 35172054: 89% reduction in hospitalisation/death in high-risk unvaccinated adults; renally dose-adjust — half-dose at eGFR 30-60, contraindicated under 30 or severe hepatic impairment; beware CYP3A drug-drug interactions, e.g. atorvastatin); alternatives — remdesivir 200 mg IV day 1 then 100 mg IV OD days 2 and 3 (3-day course), or molnupiravir 800 mg PO BD for 5 days (less effective, ~30%; avoid in pregnancy). Moderate-to-severe disease (on oxygen): (1) Dexamethasone 6 mg PO/IV OD for up to 10 days — RECOVERY (PMID 32678530): mortality reduced in oxygen-requiring (26% to 21%) and ventilated (41% to 28%) patients; NO benefit (trend to harm) in non-oxygen-requiring patients — give ONLY if on oxygen; (2) Remdesivir 200 mg IV day 1 then 100 mg IV OD days 2-5 — ACTT-1 (PMID 32445440): shortened time to recovery in hypoxaemic early disease; RNA-dependent RNA polymerase inhibitor; (3) Tocilizumab 8 mg/kg IV (max 800 mg) single dose, repeat once if no response in 8-12 h — REMAP-CAP: mortality and organ-support benefit in severe/critical with rapid progression within 24 h of new high-flow oxygen/ventilation with rising CRP/ferritin; OR baricitinib 4 mg PO OD up to 14 days (JAK1/2 inhibitor); (4) LMWH prophylaxis — enoxaparin 40 mg SC OD (20 mg if eGFR under 30; UFH 5000 IU SC TDS as alternative) in EVERY hospitalised non-bleeding patient; therapeutic anticoagulation for confirmed VTE; (5) Oxygen to target SpO2 92-96% (88-92% in COPD), escalation ladder: nasal cannula → simple face mask → non-rebreather → HFNO → CPAP/NIV → invasive mechanical ventilation → VV-ECMO; awake proning to improve oxygenation; (6) Empiric antibiotics ONLY if secondary bacterial infection suspected (procalcitonin, cultures). Critical disease (ARDS, shock, multi-organ failure): ICU; lung-protective ventilation (tidal volume 6 mL/kg PBW, plateau pressure under 30 cmH2O, driving pressure under 15, PEEP titration, prone positioning 16 h/day, neuromuscular blockade if asynchrony/severe hypoxaemia, inhaled pulmonary vasodilators as rescue, VV-ECMO for refractory); Surviving Sepsis bundle for shock (fluids, noradrenaline, broad-spectrum antibiotics within 1 h); renal replacement therapy for AKI. Drugs that are DISPROVEN and must NOT be used: hydroxychloroquine (no benefit, arrhythmia/mortality harm), lopinavir-ritonavir (no benefit), ivermectin (no benefit — TOGETHER, COVID-OUT trials), azithromycin, and convalescent plasma in late disease (modest benefit in early high-risk immunocompromised only).
Q5 (examiner's probe): How is COVID-19 managed in pregnancy, and discuss the COVID-19 vaccine platforms and their key adverse events.
COVID-19 in pregnancy carries an increased risk of ICU admission, mechanical ventilation and preterm birth, but no convincing increase in vertical transmission. Dexamethasone 6 mg OD is safe and is the corticosteroid of choice for severe maternal COVID-19 (with the caveat that dexamethasone for routine antenatal fetal lung maturation uses a separate obstetric indication protocol). Remdesivir is not contraindicated; benefit-risk favours use in hypoxaemic pregnant women. Tocilizumab can be used in life-threatening disease (limited data, no clear teratogenicity). mRNA vaccines are safe and recommended in pregnancy and lactation and reduce maternal severe disease and preterm birth; vaccination should be offered at any gestation. Timing of delivery is obstetric (not driven by COVID-19 unless maternal compromise).
Vaccine platforms: (1) mRNA — Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 (Spikevax); lipid-nanoparticle-encapsulated mRNA encoding the spike protein; ~95% efficacy against symptomatic COVID-19 (BNT162b2 — Polack et al, NEJM 2020, PMID 33301246); adverse events — reactogenicity, lymphadenopathy, anaphylaxis (rare), and mRNA-vaccine myocarditis (especially young males under-30 after the second dose, usually mild and self-limiting). (2) Viral vector — Oxford-AstraZeneca/Covishield ChAdOx1 nCoV-19, Johnson & Johnson/Janssen Ad26.COV2.S, Sputnik V (Ad26/Ad5); recombinant adenovirus encoding spike; vaccine-induced thrombosis and thrombocytopenia (VITT/TTS) — rare (1 in 25 000 to 1 in 100 000 first doses) but serious autoimmune-HIT-like syndrome (anti-PF4 antibodies, thrombosis at unusual sites — cerebral venous sinus, splanchnic; thrombocytopenia; onset 5-30 days post-vaccination); treat with non-heparin anticoagulant (argatroban, danaparoid, fondaparinux, DOAC) + IVIG, avoid heparin and platelet transfusion. Most countries restricted viral-vector vaccines to older adults or switched to mRNA after the VITT signal. (3) Inactivated — Covaxin BBV152 (Bharat Biotech) and CoronaVac (Sinovac); whole inactivated virion + alum/adjuvant; lower efficacy against symptomatic disease but good protection against severe disease; very low rates of serious adverse events. (4) Protein subunit — Novavax Nuvaxovid (recombinant spike + Matrix-M adjuvant), Corbevax. Heterologous prime-boost (mixing platforms) improves immunogenicity and is widely practised. In India (CoWIN/NHM), the programme is primarily Covishield (ChAdOx1 SII) and Covaxin (BBV152), with Corbevax, Sputnik V, and mRNA vaccines authorised subsequently; heterologous prime-boost is permitted; precaution/booster doses widely administered; vaccination recommended in pregnancy and lactation per ICMR guidance.